SELLAS Life Sciences (SLS) Cash from Discontinued Operations (2014 - 2017)
SELLAS Life Sciences (SLS) reported Cash from Discontinued Operations of 2449000.0 for Q3 2017, down 20.28% year-over-year from 3072189.77 in Q3 2016, and up 1.41% quarter-over-quarter from 2484000.0 in Q2 2017.
SELLAS Life Sciences (SLS) Cash from Discontinued Operations (2014 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has 4 years of Cash from Discontinued Operations data on file, last reported at 2449000.0 in Q3 2017.
- Cash from Discontinued Operations for Q3 2017 came in at 2449000.0, down 20.28% year-over-year; the trailing twelve-month figure through Sep 2017 was 12467000.0 (up 7.42% YoY), and the FY2016 annual result was 11685000.0, down 24.87% from the prior year.
- Cash from Discontinued Operations rose to 2449000.0 in Q3 2017 per SLS's latest filing, from 2484000.0 in the prior quarter.
- Over five years, Cash from Discontinued Operations peaked at 1059000.0 in Q1 2015 and troughed at 5004000.0 in Q1 2017.
- A 4-year average of 2785000.0 and a median of 2507000.0 in 2016 frame the typical range for Cash from Discontinued Operations.
- On a YoY basis, Cash from Discontinued Operations climbed as much as 41.31% in 2016 and fell as far as 228.14% in 2016.
- A 4-year view of Cash from Discontinued Operations shows it stood at 2440000.0 in 2014, then plunged by 76.68% to 4311000.0 in 2015, then soared by 41.31% to 2530000.0 in 2016, then advanced by 3.2% to 2449000.0 in 2017.
- Business Quant data shows SLS's Cash from Discontinued Operations at 2449000.0 in Q3 2017, 2484000.0 in Q2 2017, and 5004000.0 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discont. Ops (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 2 | Belite Bio | 55,234.00 Bn | 55,234.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,823.14 Bn | 17,823.14 Bn | - | - |
| 4 | Legend Biotech | 3,624.50 Bn | 3,624.21 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,745.73 Bn | 1,745.73 Bn | - | - |
| 6 | Evaxion A | 1,540.85 Bn | 1,540.84 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.57 Bn | 105.33 Bn | 2.59 Bn | - |
| 9 | Abivax | 93.46 Bn | 93.46 Bn | - | -59.14 Mn |
| 10 | SELLAS Life Sciences | 1.34 Bn | 1.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | -2.45 Mn |
| Sep 30, 2017 | -2.45 Mn |
| Jun 30, 2017 | -2.48 Mn |
| Jun 30, 2017 | -2.48 Mn |
| Mar 31, 2017 | -5.00 Mn |
| Mar 31, 2017 | -5.00 Mn |
| Dec 31, 2016 | -2.53 Mn |
| Dec 31, 2016 | -2.53 Mn |
| Sep 30, 2016 | -2.04 Mn |
| Sep 30, 2016 | -2.04 Mn |
| Jun 30, 2016 | -3.64 Mn |
| Jun 30, 2016 | -3.64 Mn |
| Mar 31, 2016 | -3.48 Mn |
| Mar 31, 2016 | -3.48 Mn |
| Dec 31, 2015 | -4.31 Mn |
| Dec 31, 2015 | -4.31 Mn |
| Sep 30, 2015 | -1.07 Mn |
| Sep 30, 2015 | -1.07 Mn |
| Jun 30, 2015 | -2.92 Mn |
| Jun 30, 2015 | -2.92 Mn |